Article | Published: June 10, 2026
Food-dependent prolonged-release oral minoxidil suppresses peak systemic exposure: dissolution and pilot pharmacokinetic characterization
Authors: Andrew Bakst, Andrew Verbinnen, Mitchell Graumenz, Rutu Jagtap, Lamia Tahsin, Sneha Gowda, Aarzoo Parikh, Zachary Schrier, Aonia Traxler, Blake Bloxham
MINX was designed to separate the minoxidil exposure curve from the sharp early spike of immediate-release oral dosing.
Abstract
Low-dose oral minoxidil is increasingly used off-label for androgenetic alopecia, but the available oral tablet is an immediate-release cardiovascular drug. This paper characterizes MINX, a lipid-matrix prolonged-release oral minoxidil formulation, using dissolution testing and a pilot pharmacokinetic comparison of fed and fasted dosing.
The central finding is pharmacokinetic: under fed conditions, MINX produced a flat, delayed, low-peak serum profile while preserving total exposure in the range of a published 5 mg immediate-release reference. The pilot does not claim efficacy or clinical safety; it defines the formulation behavior and the next confirmatory study.
Study design
The work had two parts. First, the formulation was tested in vitro at acidic and small-intestinal pH to determine whether it released minoxidil gradually rather than as a bolus. Second, serum minoxidil was measured after single 5 mg MINX doses in a two-subject pilot: one subject dosed with food and one subject dosed fasted.
Formulation
Lipid-matrix prolonged-release oral minoxidil
Dose
5 mg MINX
In vitro work
Dissolution at pH 1.2 and pH 6.8
In vivo work
Two-subject pilot pharmacokinetic study
Key findings
| Measure | Result |
|---|---|
| Dissolution | MINX released progressively over 12 hours, while the immediate-release comparator released almost completely in the first sampling window. |
| Fed pharmacokinetics | The fed profile rose gradually through the 8-hour sampling window and was projected to peak around 9-10 hours. |
| Peak exposure | Modeled fed Cmax was about 6.5 ng/mL, roughly 6-fold lower than the 37.2 ng/mL immediate-release reference. |
| Total exposure | Modeled fed AUC was about 60 ng*h/mL, broadly comparable to the 55.1 ng*h/mL immediate-release 5 mg reference. |
| Food effect | Fasted dosing produced substantially lower exposure, consistent with gastric transit truncating matrix release. |
Interpretation
The paper frames MINX as a formulation problem: immediate release oral minoxidil produces a high early systemic peak, but the follicular rationale for minoxidil depends on sustained substrate availability for local sulfation. A lower, flatter exposure curve may be better aligned with that biology while reducing peak-driven systemic burden, but this remains a hypothesis until tested prospectively.
The food effect is central. The fasted profile suggests the matrix can transit beyond the useful absorption window before release is complete. In this formulation, taking MINX with food is not a minor preference; it is part of the intended pharmacokinetic behavior.
Limitations
This is a two-subject pilot with one fed and one fasted participant, not a powered clinical trial or a within-subject crossover. Fed Cmax and the post-8-hour tail were modeled because the fed curve was still rising at the last measured time point. The study did not measure hair growth, blood pressure, heart rate, edema, body weight, or cardiovascular outcomes.
Those constraints are why the paper treats the result as a formulation and pharmacokinetic characterization, not as proof that MINX is safer or more effective than immediate-release oral minoxidil.
Next step
The appropriate confirmatory study is a powered within-subject crossover that directly compares MINX with immediate-release oral minoxidil while measuring pharmacokinetics and concurrent cardiovascular endpoints.
For the product-science explainer and plotted pharmacokinetic curves, see the MINX treatment-science page.